Navigation Links
Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
Date:5/15/2008

f hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern because of the aging of the population. Patients suffering from atrial fibrillation have twice the risk of death, an increased risk of stroke and cardiovascular complications, including congestive heart failure. Furthermore atrial fibrillation considerably impairs patients' lives, mainly because of their inability to perform normal daily activities due to complaints of palpitations, chest pain, dyspnoea, fatigue or light-headedness, without consideration of the cumbersome and sometime serious constraints imposed by current therapies of atrial fibrillation.

"In atrial fibrillation where treatment morbidity-mortality benefit still needed to be demonstrated, ATHENA is a unique trial using clinically relevant outcomes such as cardiovascular hospitalization or death as the primary endpoint. In this regard, the trial has clearly achieved these safety and efficacy endpoints," said Dr Stefan H. Hohnloser, J.W. from the Goethe University, Division of Clinical Electrophysiology, Frankfurt, Germany, who served as co-principal investigator of the ATHENA study. "As a consequence, dronedarone is the first potential treatment for atrial fibrillation, which was demonstrated in the ATHENA trial to reduce cardiovascular hospitalization or mortality in patients with AF," he added.

The most frequently reported adverse events of Multaq(R) vs. placebo induced gastro-intestinal effect (26% vs. 22%), skin disorder (10% vs. 8%, mainly rash) and increased blood creatinine (4.7% vs. 1%). The mechanism of blood creatinine increase (inhibition of creatinine secretion at the renal tubular level) was well defined, in a separate study of healthy volunteers. Multaq(R) showed a rate of pro-arrhythmia similar to placebo and no excess of hospitalizations for congestive heart failure. There was a s
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
2. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
3. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
4. Hospital Launches Landmark Emergency Medicine Project
5. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
6. Viatronix V3D-Colon Utilized in Another Landmark Study
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
11. St. Jude Study Shows How T Cells Machinery Dials Down Autoimmunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 15 Theranostics Health (TH) today,announced that ... Registration from the,Federal Government. This, along with ... Maryland Department of Health & Mental Hygiene, ... testing in the,disciplines/specialties of Immunology/protein microarray and,Pathology/histopathology., ...
... With Deep Vein, Thrombosis; $10 Million National ... Drug- Device Technique Can Prevent Post-Thrombotic Syndrome, FAIRFAX, ... trial of a catheter-based treatment for deep vein thrombosis,-- ... with clot,removal devices to prevent post-thrombotic syndrome in patients ...
Cached Medicine Technology:Theranostics Health Receives Green Light to Perform Clinical Testing 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 3Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 4
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... January 22, 2015 Lower-Auto-Insurance.com has released a new ... in a car for reducing the costs of an auto ... also be able to get lower prices for their vehicle insurance ... important role in determining policy costs. Because of this, drivers ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... in brain cells may hold clues for Parkinson,s treatment, researchers ... they,ve discovered collections of brain cells that may play a ... in things like playing the piano and driving a car. ... found the cells in the prefrontal cortex and striatum parts ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... Neurologists at the University at Buffalo are beginning ... on the cause of multiple sclerosis (MS). The researchers ... result from narrowing of the primary veins outside the ... CCSVI. CCSVI is a complex vascular condition ...
... Sexual trauma also associated with women,s urinary tract symptoms, ... -- Psychiatric disorders and sexual trauma in women increase ... as incontinence and overactive bladder, a new study finds. ... -- the Urogenital Distress Inventory-6 and Incontinence Impact Questionnaire-7 ...
... antidepressants for depression never get relief. Why? Because ... to treat it aim at the wrong target, according to ... The medications are like arrows shot at the outer rings ... A study from the laboratory of long-time depression researcher Eva ...
... researchers find , FRIDAY, Oct. 23 (HealthDay News) -- A ... seven-day course in reducing pain after children have their tonsils ... in the October issue of the Archives of Otolaryngology ... tonsillectomy can make children reluctant to eat and drink, leading ...
Cached Medicine News:Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 3Health News:Buffalo neurologists investigate possible new underlying cause of MS 4Health News:Bladder Problems May Often Be Related to Mental Health 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3Health News:After Tonsillectomy, Short-Term Antibiotics Effective: Study 2
... WristOx® 3100 is a small, ... be worn comfortably on the ... daily activities and for overnight ... the WristOx is intended to ...
... The PulseOx 5500TM is the ... blood oxygen saturation and heart rate ... The PulseOx 5500TM uses SPO Medicals ... device which is more usable for ...
All-in-One Fingertip Oximeter...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: